The Efficacy and Safety Difference Between Daridorexant and Suvorexant
DOI:
https://doi.org/10.54097/mc374q32Keywords:
Insomnia; Dridorexant; suvorexant; efficacy; security.Abstract
The prevalence of insomnia is rising in today's culture under the influence of many factors. However, experts have long been concerned about the negative consequences and effects of hypnotic medicines. Currently, more and more researchers are focusing on the effects of drugs that target orexin receptors on sleep. Both daridorexant and Suvorexant are two effective dual orexin receptor antagonists in treating insomnia. According to the data collected from Google Scholar, JSTOR, NCBI, and PMC, the comparison of the effectiveness and the abuse potential between daridorexant and suvorexant is concluded. Suvorexant already is a common medicine for patients. The best dose for suvorexant is 30/40mg. Suvorexant has some unserious side-effects like nasopharyngitis. Daridorexant is a relatively new drugs that just enter the market in 2022. It has more function than Suvorexant like improving day-time function and sleep structure. The best dose for daridorexant is 50 mg. Daridorexant has unserious side-effects like fatigue and somnolence.
Downloads
References
Maurice M Ohayon. Epidemiology of Insomnia: What We Know and What We Still Need to Learn? Sleep Medicine Review, 2002, 6: 97–111.
Daniel J Buysse, Jules Angst, Alex Gamma, et al. Prevalence, Course, and Comorbidity of Insomnia and Depression in Young Adults. Sleep, 2008, 31(4): 473–480.
Anthony Markham. Daridorexant: First Approval. Drugs, 2022, 82(5): 601-607.
Catherine Brisbare-Roch, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine, 2007, 13(2):150-155.
Catherine Roch, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl), 2021 238(10): 2693-2708.
Tina Nie, Hannah A Blair. Daridorexant in Insomnia Disorder: A Profile of Its Use. CNS Drugs, 2023, 37(3): 267-274.
Alexander Treiber, et al. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. The Journal of pharmacology and experimental therapeutics, 2017, 362: 489–503.
Clemens Muehlan, et al. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clinical pharmacology and therapeutics, 2018, 104: 1022–1029.
Christoph Boss, et al. The Quest for the Best Dual Orexin Receptor Antagonist (daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem, 2020, 15: 2286–2305.
Anthony L Gotter, et al. The Duration of Sleep Promoting Efficacy by Dual Orexin Receptor Antagonists is Dependent Upon Receptor Occupancy Threshold. BMC neuroscience, 2013, 14: 90.
Emmanuel Mignot, et al. Safety and Efficacy of Daridorexant in Patients with Insomnia Disorder: Results from Two Multicentre, Randomised, Double-blind, Placebo-Controlled, Phase 3 Trials. The Lancet. Neurology, 2022, 21(2): 125–39.
Idorsia Pharmaceuticals US Inc. QUVIVIQ (daridorexant) tablets, for oral use. US prescribing information, 2022. https://www.idorsia.us/documents/us/label/Quviviq_PI.pdf.
Catherine Roch, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology, 2021, 238: 2693–2708.
Dieter Kunz, et al. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. CNS Drugs, 2023, 37: 93–106.
W Joseph Herring, et al. Suvorexant in Patients with Insomnia: Results from Two 3-Month Randomized Controlled Clinical Trials. Biological psychiatry, 2016, 79(2): 136–148.
Citrome L. Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 2014, 68(12): 1429-1441.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
